# Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer

> **NCT01934634** · PHASE1 · UNKNOWN · sponsor: **US Oncology Research** · enrollment: 24 (estimated)

## Conditions studied

- Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** LCL161
- **DRUG:** Gemcitabine
- **DRUG:** nab-Paclitaxel

## Key facts

- **NCT ID:** NCT01934634
- **Lead sponsor:** US Oncology Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-03
- **Primary completion:** 2016-03
- **Final completion:** —
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2015-11-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01934634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01934634, "Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01934634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*